

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

April 7-11, 2019 • Beaver Run Resort • Breckenridge, Colorado, USA

Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh

Sponsored by Bioverativ Therapeutics, Roche, Incyte Corporation and Valerion Therapeutics

Abstract & Scholarship Deadline: December 11, 2018 / Abstract Deadline: January 9, 2019 / Discounted Registration Deadline: February 6, 2019

SUNDAY, APRIL 7

Arrival and Registration

MONDAY, APRIL 8

Welcome and Keynote Session

George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA
Target Identification and Developing Antibodies for Clinical Application

Jennifer R. Cochran, Stanford University, USA
Emerging Strategies for Developing Next-Generation Protein Therapeutics

Mechanisms of Action for Depleting Antibodies

Mark S. Cragg, University of Southampton, UK
Targeting B Cells with Antibodies: From Oncology to Autoimmunity

Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany
Optimal Formats for Target Cell Deletion

Short Talk(s) Chosen from Abstracts

Workshop 1: Engineering (Bispecific) Antibodies

Short Talks Chosen from Abstracts

Antibody Engineering

Janine Schuurman, Genmab B.V., Netherlands
Engineering Non-Classical Antibody Formats

Feng Wang, Institute of Biophysics, China
Engineering Antagonistic and Agonistic Antibodies

Germaine Fuh, 23andMe, USA
Engineering Antibody Specificity and Stability Using Deep Sequencing

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, APRIL 9

Bispecific and Engineered Antibodies for Cancer Immunotherapy

Nai-Kong V. Cheung, Memorial Sloan-Kettering Cancer Center, USA
Cancer Immunotherapy with Bispecific Antibodies

Christian Klein, Roche, Switzerland
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy

Marie H. Kosco-Vilbois, NovImmune SA, Switzerland
Bispecific CD47 Antibodies for Treatment of Cancer and Autoimmunity

John R. Desjarlais, Xencor, USA
Bispecific Antibodies for T Cell Recruitment and T Cell Activation

Short Talk(s) Chosen from Abstracts

Antibodies for Infectious Diseases

David D. Ho, Aaron Diamond AIDS Research Center, USA
Novel Antibodies for HIV Therapy and Prevention

JoAnn A. Suzich, MedImmune, USA
Antibodies for Prevention and Treatment of Viral Infections

Kartik Chandran, Albert Einstein College of Medicine, USA
Catching Viruses in Endosome Using Bispecific Antibodies

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, APRIL 10

Next Generation Antibody Drug Conjugates

Ronit Mazor, Medimmune, Inc., USA
Progress with Antibody Toxin Fusion Proteins and Overcoming Immunogenicity

Richard J. Gregory, ImmunoGen, Inc., USA
Optimizing the Activity of Antibody Drug Conjugates

John M. Lambert†, ImmunoGen, Inc., USA
The Promise of ADCs: A Simple Concept, Difficult to Execute! Where Are We Now?

W. Michael Kavanaugh, CytomX Therapeutics, Inc., USA
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies

Short Talk(s) Chosen from Abstracts

Delivering Antibodies into the Brain

Joy Yu Zuchero, Denali Therapeutics Inc, USA
Novel Approaches for Delivery of Antibodies into the Brain

Per-Ola Freskgård, F. Hoffmann-La Roche, Switzerland
Crossing the Blood Brain Barrier with Antibodies to Access Brain Targets

Allan Jensen, Lundbeck, Denmark
Antibody based Therapies for Neurodegenerative Diseases

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, APRIL 11

Bispecific Antibodies and Antibody Like Molecules

Christoph Rader, The Scripps Research Institute, USA
Chemically Programmed Antibodies

James A. Ernst, Genentech, Inc., USA
A Novel Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH

Andreas G. Plückthun, University of Zürich, Switzerland
Engineering DARPins for Delivery into Cells

Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Next-Generation Chimeric Antigen Receptors

Short Talk(s) Chosen from Abstracts

Workshop 2: Antibodies for Immunological Applications

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

April 7-11, 2019 • Beaver Run Resort • Breckenridge, Colorado, USA

Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh

Sponsored by Bioverativ Therapeutics, Roche, Incyte Corporation and Valerion Therapeutics

Abstract & Scholarship Deadline: December 11, 2018 / Abstract Deadline: January 9, 2019 / Discounted Registration Deadline: February 6, 2019

Short Talks Chosen from Abstracts

Beyond Checkpoint Blockade: Novel Approaches for Immunotherapy

Mikael C. I. Karlsson, Karolinska Institutet, Sweden
Anti-Marco Antibodies in Tumor Immunotherapy

Sean Hua Lim, University of Southampton, UK
Targeting CD27

Elaine M. Paul, GlaxoSmithKline, USA
GSK 3359609 a Non-Depleting IgG4 Anti-ICOS Antibody

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, APRIL 12

Departure